Objective: To investigate the interrelations of serum vitamin B12 markers with brain volumes, cerebral infarcts, and performance in different cognitive domains in a biracial population sample cross-sectionally.
vitamin B12 and related metabolites to WMHV, cerebral infarcts, and TBV among black and white CHAP participants. We sought to investigate whether these vitamin B12related markers were associated with test scores of individual cognitive domains and whether cognitive effects associated with these vitamin B12-related metabolites, if observed, were independent of brain measures.
METHODS Study population. Study subjects were participants in CHAP, an ongoing, geographically defined cohort of older residents 65 years and older on the south side of Chicago. A total of 6,158 participated in the initial cycle of baseline interviews during 1993-1996 (79% participation overall; 81% among blacks, 75% among whites). In-home interviews are conducted in 3-year cycles on all participants. Stratified random samples of participants are drawn at each cycle for clinical evaluation of dementia that included neuropsychological testing, neurologic examination, and laboratory tests. 8 MRI was requested of all clinically evaluated persons in cycles 3, 4, and 5. The Institutional Review Board of Rush University Medical Center approved the study; all participants gave written informed consent.
Blood drawn at each clinical evaluation cycle is routinely analyzed for measurement of serum vitamin B12 levels. In addition, we analyzed several vitamin B12 markers, including homocysteine, MMA, and other related metabolites-cystathionine, and 2-methylcitrate in stored blood of participants.
This report describes analyses relating serum vitamin B12 and B12-related metabolites to cognitive performance at cycle 2. A total of 842 persons were clinically evaluated in cycle 2. Only 682 had stored serum available for biochemical analyses of vitamin B12 markers and related metabolites, of which only 121 had MRI scans on average 4.6 years later.
Clinical assessment and cognitive measures. Cycle 2 clinical evaluations were conducted between 1996 and 1999 in subjects' homes by a team of a neurologist, nurse clinician, neuropsychological technician, and a phlebotomist. Neuropsychological testing included a battery of 17 cognitive function tests. 9 These included 1) 7 measures of episodic memory: Word List Memory, Recall, and Recognition and immediate and delayed recall of Story A from the Logical Memory and the East Boston Story; 2) 2 measures of visuospatial ability or perceptual organization: a short form of Judgment of Line Orientation and Standard Progressive Matrices; 3) 2 measures of perceptual speed: an oral version of the Symbol Digit Modalities Test and Number Comparisons; 4) 2 measures of semantic memory: a 15-item version of the Boston Naming Test, and short form of the National Adult Reading Test; and 5) 3 measures of working memory: Digit Span Forward, Digit Span Backward, and Digit Ordering. To minimize floor and ceiling effects of the individual tests, summary measures of each cognitive domain were constructed by converting raw scores on each individual test (using the mean and SD for the CHAP population at baseline) to z scores, and averaging the z scores. A measure of global cognitive function was also formed by averaging the z scores on all 17 tests. 9 Diagnosis of dementia was made by an experienced neurologist and required the loss of cognitive function by neurologic assessment and impairment in 2 or more areas on the cognitive performance testing. 10 Biochemical assessment of vitamin B12 status. For the present effort, biochemical analyses were performed on nonfast-ing blood. Earliest samples included in these analyses were collected August 1997, the latest in November 2000; hence, sampling occurred during both the voluntary and mandatory folate fortification of the US food supply. Serum vitamin B12 was measured by competitive displacement immunoassay (Quest Laboratories, Wooddale, IL) immediately following the clinical evaluation because this measurement was part of a routine diagnostic panel. From frozen sera aliquots stored at Ϫ80°C for 7-10 years, the other vitamin B12 markers (methylmalonic acid [MMA], homocysteine, 2-methylcitric acid, and cystathionine) were measured using stable-isotope dilution and capillary gas chromatographymass spectrometry (Metabolite Labs at the University of Colorado Health Sciences Center, Denver, CO). 11, 12 MRI. See also e-Methods on the Neurology ® Web site at www.neurology.org. Subjects were imaged on a General Electric 1.5-T scanner (Excite platform, version 11) and the following imaging sequences were obtained: fluid-attenuated inversion recovery: repetition time (TR) ϭ 11,000, echo time (TE) 144, inversion time (TI) 2,250, 22 cm field of view (FOV), 3 mm slice thickness, 192 ϫ 256 acquisition matrix; spoiled gradient: TE minimum, 20 degree flip angle, 24 cm FOV, 1.5 mm slice thickness with 256 ϫ 256 acquisition matrix; double spin echo: TR ϭ 2,100, TE ϭ 30/92, 22 cm FOV, 4 mm slice thickness, with 256/192 acquisition matrix. Axial images were angled to be parallel to the anterior and posterior commissure lines. After acquisition of the MRI scans, digital information was transferred to the laboratory of Dr. Charles DeCarli for processing and analysis.
White matter hyperintensity segmentation was performed by a 2-step process according to previously reported methods. [13] [14] [15] WMHV was expressed in proportion to total cranial volume to correct for head size and log transformed to create a normal distribution (log-WMHV) for analysis as a continuous measure. TBV was computed as the ratio of total brain parenchymal volume to total cranial volume. The presence or absence of cerebral infarcts was determined manually by the operator who considered the size, location, and imaging characteristics of the lesion. 16 Only lesions 3 mm or larger were considered cerebral infarcts. Repeat analysis of intrarater and interrater reliabilities of MRI measures for the purpose of this study were consistently above 0.90. [17] [18] [19] [20] Definition of covariates or mediators. Sex and race were obtained at the time of the census and verified at the baseline population interview. Age was computed from self-reported birth date and date of the MRI evaluation. Education was computed from self-reported highest grade or years of formal education. Height, current smoking status, and lifetime daily alcohol use (drinks/day) were based on self-report during the cycle 2 population interview. Participant's weight without shoes was measured on a digital freestanding scale. From these measures, body mass index (BMI) in kg/m 2 was calculated. Hypertension was defined as self-reported hypertension or measured systolic blood pressure Ն160 mm Hg or diastolic pressure Ն95 mm Hg. Participants were categorized according to the presence or absence of one or more APOE4 alleles. Serum creatinine measurements were performed by Rush University Medical Laboratories.
Statistics. Our primary objective was to expand on our previous findings of association between levels of MMA and vitamin B12 and cognitive decline by examining the relations between these serum markers of vitamin B12 status to brain MRI measures. In addition, we sought to explore the relations of serum vitamin B12 markers with different cognitive domain scores. 7 In separate models, we used multiple linear regression (SAS/STAT software version 9.2) to regress either brain volume or cognitive score outcome measures on each vitamin B12 marker. Logistic regression models were used to examine the associations of vitamin B12 markers on the presence or absence of infarcts. For primary analyses all models were controlled for age, sex, education, race, serum creatinine concentrations, and time elapsed between blood sampling and MRI evaluation (MRI lag) and the MRI instrument. Because homocysteine and MMA are elevated when there is renal failure, 12 serum creatinine level was included in all models to account for possible confounding.
In secondary analyses, because of the small sample size we examined confounding by other factors by including them one at a time in the primary model. Among these factors were APOE4, dementia diagnosis, hypertension, BMI, smoking status, and lifetime alcohol intake. We examined possible interactions by age, sex, race, APOE4, dementia, and hypertension with the inclusion of multiplicative terms for each vitamin B12-related marker and the effect modifier in the primary model. To examine potential mediation effects on observed associations of vitamin B12 markers with cognitive function, we added a term for each MRI measure to each primary model, noting differences in the effect estimates and p values with and without terms in the model.
RESULTS
At cycle 2 (baseline for our analyses) half of the analytic sample was female (51%) and 45% was white (table 1). Global cognitive scores ranged from Ϫ2.18 to 1.42 with a mean of 0.23. Risk factors and comorbidities were similar between the full and analyzed samples except that the analytic sample had fewer female participants, more black participants, and only 2.5% of the analytic the higher the concentrations of these markers, the lower the scores. Higher MMA concentrations were also associated with reduced perceptual speed, and higher cystathionine and 2-methylcitrate concentrations were each associated with poorer semantic memory. These associations remained in analyses that adjusted individually for BMI, smoking status, lifetime alcohol intake, hypertension, dementia, or APOE4 (data not shown). In further analyses, there was no evidence for effect modification by these factors.
B12 markers and brain MRI measures. Similar to our findings for cognitive function, vitamin B12 levels were not associated with any of the MRI measures in models adjusted for age, sex, race, education, and serum creatinine (table 3) . Homocysteine concentration was the only vitamin B12 indicator that was associated with WMHV; WMHV increased by 0.103 units per mol/L increase in homocysteine concentration. Higher levels of each of the B12- related markers (that is, serum homocysteine, MMA, cystathionine, and 2-methylcitrate concentrations) were significantly associated with decreased TBV. We also examined whether these associations were modified by level of age, sex, race, education, APOE4, or dementia. The only evidence of effect modification was stronger adverse effects on TBV by cystathionine among persons with the APOE4 allele ( p interaction ϭ 0.02). The influence of hypertension on the association between homocysteine and TBV was marginal ( p interaction ϭ 0.069).
Investigation of potential mechanisms. We explored potential underlying mechanisms for the associations between the vitamin B12 markers and cognitive function by adding covariates for the individual MRI measures into these models. The association of homocysteine and global cognitive performance was attenuated (␤ ϭ Ϫ0.024, p ϭ 0.08) when we adjusted for WMHV. Adjustment for cerebral infarcts also attenuated the homocysteine association to a similar extent (␤ ϭ Ϫ0.024, p ϭ 0.08), though when we adjusted for TBV, we observed no marked attenuation (␤ ϭ Ϫ0.029, p ϭ 0.04). Associations between global cognitive function and each of MMA, cystathionine, and 2-methylcitric acid were attenuated and no longer statistically significant with adjustment for TBV (for MMA, ␤ ϭ Ϫ0.001, p ϭ 0.14). Both TBV and WMHV accounted for the associations between B12 markers and episodic memory (for MMA, ␤ ϭ Ϫ0.001; p value ϭ 0.10). Adjustment for any of the MRI measures attenuated the observed associations between perceptual speed and MMA (for example with WMHV, ␤ ϭ Ϫ0.001; p value ϭ 0.16). In contrast, the association noted for semantic memory and cystathionine was not markedly attenuated when TBV was entered into the model (␤ ϭ Ϫ0.03, p ϭ 0.048). DISCUSSION This report describes the associations of serum vitamin B12 and vitamin B12-related metabolites to cognitive performance at cycle 2 and to MRI measurements on average 4.6 years later. Associations are observed for concentrations of vitamin B12 and related markers that are considered reflective of adequate vitamin status.
The finding of associations between several of the vitamin B12 markers and global cognitive scores is consistent with our previous report of 516 CHAP subjects 7 as well as that of others, [21] [22] [23] [24] [25] but not all. 26 Associations between brain MRI measures (in particular, TBV and WMHV) and global cognition as well as performance in multiple domains have been reported previously by our group, but not in relation to vitamin B12 status. 1 In the present report, we did not observe associations between the vitamin B12 mark-ers and cerebral infarcts. This observation is in contrast to reports by other groups who have described a greater number of infarcts and more WMH burden with higher homocysteine concentrations. [27] [28] [29] Absence of an association in our study may be due to the few subjects. The observation of effect modification by APOE4 on the association of cystathionine and TBV is consistent with evidence that the genotype and low B vitamin status confers greater vulnerability to cognitive deficits. 30 In the present study, the potential mediation of MRI measures on the relation of vitamin B12related markers to cognition has been investigated. Serum homocysteine levels were associated with cognitive performance which was independent of TBV. Others have noted a relationship between homocysteine and cognition 31, 32 but not simultaneously with brain MRI measures. In a British cohort where mandatory folate fortification is in place, a comprehensive set of vitamin B12 markers were examined in association with brain atrophy over 5 years in 107 older adults. After adjustment for confounders, neither homocysteine nor MMA was predictive of brain atrophy, though vitamin B12 and its carrier, holotranscobalamin, were. 6 In the VITACOG trial, treatment with a supplement containing vitamin B6, vitamin B12, and folate for 2 years reduced homocysteine levels and slowed brain atrophy in British adults with mild cognitive impairment, but concomitant changes in cognitive scores were not reported. 33 Associations between several vitamin B12 indicators and white matter lesions and with cognitive function were reported in the Rotterdam Scan Study but potential mediation effects were not examined. 26 Our data suggest that both vascular and nonvascular mechanisms play a role in vitamin B12 status. The vascular mechanism is consistent with the attenuation of the relation between homocysteine and cognitive performance when cerebral infarcts were entered in the model. For the nonvascular contribution, small differences in vitamin B12 markers may alter the integrity of white matter, specifically by modifying the extent of myelin damage. Areas of demyelination on brain MRI have been described in vitamin B12-deficient patients or in those with diseases that affect vitamin B12 metabolism. [33] [34] [35] Thus, our findings lend support for the contention that poor vitamin B12 status is a risk factor for brain atrophy and possibly WMHV which in turn may contribute to cognitive impairment. The single MRI measure in the present study prevents direct investigation of whether poor vitamin B12 status results in cognitive decline by promoting faster rates of total brain atrophy or demyelination in selected white matter areas. On the basis of repeated MRI scans, brain atrophy associated with cognitive decline appears to be a slow process; brain atrophy rates among adults aged 70 years or more ranged from 0.7% to 1.1% per year. 6, 33 A distinct contribution made by our group is a comprehensive study of the metabolic indicators of vitamin B12 status and the possible role it has on both cognitive performance and brain measures. Both homocysteine and MMA accumulate when insufficient vitamin B12 is available as a cofactor for 2 separate reactions; cystathionine and 2-methylcitric acid also accumulate. 11, 12 Folate and vitamin B6 status may also contribute to elevated cystathionine and 2-methylcitric acid, however. Only MMA accumulates specifically in response to low vitamin B12 status. A limitation to this study is the absence of serum folate and vitamin B6 determinations. Strengths of this study include a sensitive imaging method to assess WMHV and TBV at the same MRI facility, a well-characterized biracial cohort of older adults, and use of validated measures of cognitive function.
Marginal vitamin B12 status in older age 36 is frequently missed by measurement of serum vitamin B12 levels alone. Our findings suggest that MMA, the specific marker of B12 deficiency, may affect cognition by reducing TBV whereas the effect of homocysteine on cognition may be mediated through increased WMHV and cerebral infarcts. Vitamin B12 status as reflected by functional markers such as homocysteine and MMA concentrations and the relations to brain changes on MRI and cognitive testing deserves further examination.
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